Introduction
Ever since its inception, in August 1978 in Singapore, APASL (Asian Pacific Association for the Study of the Liver) has never looked back and continually adheres to its goal of advancing the science and practice of Hepatology. Today it is one of the leading associations based on the investigation and treatment of liver diseases in the world and the largest scientific body to uphold the standards of profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region.
APASL's main objectives are to promote the latest scientific advancements and education of hepatology science, exchange of information and the development of consensus, encourage the practice of medicine in liver diseases and also coordinate scientific studies between various scientists and clinicians throughout the region. We hold scientific educational symposia/conferences developed by leading hepatologists periodically. Our events feature expert speakers presenting the finest data on the most important topics of liver diseases with high quality scientific technical presentations, followed by varied supporting programs. Each of our events is intended to meet the growing demands of hepatology as the core medical specialty and offers participants the right platform to exchange research, discuss outcomes, and interact with colleagues, focused on liver diseases. Our members include all medical professionals dedicated to hepatology-its research and practice . We cover the region from Manchuria in the North, to Australia in the South, to the Pacific Islands in the East and Iran in the West. Our members are elected on their documented scientific publications. Mentoring, sharing of knowledge and dedication to professional growth and development are among the core values of APASL and its members.
Call for paper
Important date
Submission Topics
Acute Liver Failure and Artificial Liver Support-Clinical
• CA-01 Acute Liver Failure and Artificial Liver Support-Clinical
Acute Liver Failure and Artificial Liver Support- Basic
• BA-01 Acute Liver Failure and Artificial Liver Support-Basic Science
Alcoholic Liver Disease-Clinical
• CAL-01 Alcoholic Liver Disease: Clinical and Therapeutic
Alcoholic Liver Disease-Basic
• BAL-01 Alcoholic Liver Disease: Experimental
Hepatitis B and D-Clinical
• CB-01 Diagnostics, Epidemiology, Prevention, Natural History
• CB-02 Therapeutics: New and Approved
Hepatitis B and D-Basic
• BB-01 Virology, Pathogenesis, and Immunology
Biliary and pancreatic Neoplasia other than Liver cancer-Clinical
• CBN-01 Diagnostics and Liver Imaging of biliary and pancreatic neoplasia
• CBN-02 Prognosis : biliary and pancreatic neoplasia
• CBN-03 Surgery and Loco-Regional Therapy for biliary and pancreatic neoplasia
• CBN-04 Targetted and systemic therapies for biliary and pancreatic neoplasia
Biliary and pancreatic Neoplasia other than Liver cancer-Basic
• BBN-01 Experimental carcinogenesis of biliary and pancreatic neoplasia
Hepatitis C-Clinical
• CC-01 Diagnostics, Epidemiology, Natural History
• CC-02 Therapeutics: Preclinical and Early Clinical Development
• CC-03 Therapeutics: New Agents (not approved, phase 2-3)
• CC-04 Therapeutics: Approved Agents
Hepatitis C-Basic
• BC-01 Virology, Pathogenesis, and Immunology
Cholestatic and Autoimmune Liver Diseases-Clinical
• CCA-01 PBC/PSC and Other Cholestatic Disease: Clinical and Therapeutics
• CCA-02 Autoimmune Liver Disease: Clinical and Therapeutics
Cholestatic and Autoimmune Liver Diseases-Basic
• BCA-01 Transport, Bilirubin, Cholesterol, Lipids and Bile Salts, Cholangiocyte Biology and Experimental Cholestasis
• BCA-02 Autoimmune Liver Disease:Experimental
Drug Induced Liver Injury-Clinical
• CD-01 Predictors of Drug Toxicity and Therapy
Drug Induced Liver Injury-Basic
• BD-01 Pathogenesis and Mechanisms
• BD-02 Drug Metabolism, and Toxicity
Hepatitis A and E-Clinical
• CE-01 Hepatitis A and E- Clinical and Therapeutic
Hepatitis A and E-Basic
• BE-01 Hepatitis A and Experimental
Liver Fibrogenesis and Non-Parenchymal Cell Biology-Clinical
• BF-01 Imaging and Noninvasive Markers of Liver Fibrosis
• BF-02 Clinical and Translational Fibrosis Research and Therapy
Liver Fibrogenesis and Non-Parenchymal Cell Biology-Basic
• BF-01 Basic Fibrosis Research and Stellate Cell Biology
Genetic and Metabolic Disease-Clinical
• CG-01 Hemochromatosis, Wilson Disease, ∝-1 Antitrypsin Deficiency-Clinical
CG-02 Other genetic and metabolic disorders-Clinical
Genetic and Metabolic Disease-Basic
• BG-01 Hemochromatosis, Wilson Disease, ∝-1 Antitrypsin Deficiency-Experimental
BG-02 Other genetic and metabolic disorders-Experimental
Inflammation and Immunology-Basic
• BI-01 Animal Models
• BI-02 Innate Immunity
• BI-03 Adaptive Immunity
• BI-04 Mechanisms of Injury and others
Liver Cancer -Clinical
• CLC-01 Diagnostics and Liver Imaging of hepatocellular carcinoma
• CLC-02 Prognosis : Hepatocellular Carcinoma
• CLC-03 Liver transplantation, Surgery and Loco-Regional Therapy for Hepatocellular Carcinoma
• CLC-04 Targetted and systemic therapies for Hepatocellular Carcinoma
Liver Cancer -Basic
• BLC-01 Experimental Hepatocarcinogenesis
Liver Transplantation and Liver Surgery-Clinical
• CLTS-01 Donor and Allocation Issues; Living Donor and Split Liver Transplantation,
• CLTS-02 Immunosuppression, Outcomes, Complications of liver transplantation
• CLTS-03 Viral Hepatitis and liver transplantation
• CLTS-04 Hepatobiliary Surgery
Liver Transplantation and Liver Surgery-Basic
• BLTS-01 Cellular Immunobiology, Preservation and Cell Transplantation, Experimental
Molecular and Cellular Biology and Stem Cell Therapy -Basic
• BM-01 Cell Structure; Function; Signal Transduction, Nuclear Receptors
• BM-02 Gene Expression and Gene Therapy
• BM-03 Stem Cell Biology- Basic Sciences
• BM-04 Stem cell therapy: Clinical
Non-alcoholic Fatty liver Disease-Clinical
• CNA-01 NAFLD: Clinical and Therapeutic
Non-alcoholic Fatty liver Disease-Basic
• BNA-01 NAFLD: Experimental
Portal Hypertension and Other Complications of Cirrhosis-Clinical
• CP-01 Ascites, Renal Dysfunction and Hepatorenal Syndrome
• CP-02 Varices and Bleeding
• CP-03 Encephalopathy and Infections and Other Complications
• C-P04 Acute on Chronic Liver Failure
Portal Hypertension and Other Complications of Cirrhosis including ACLF-Basic
• BP-01 Experimental\
Pediatric Hepatology-Clinical
• CPD-01 Biliary Atresia and Cholestasis
• CPD-02 Viral and Autoimmune Hepatitis
• CPD-03 Metabolic and Genetic Diseases
• CPD-04 Pediatric Liver Transplantation
Pediatric Hepatology-Basic
• BPD-01 Pediatric Liver Disease – Basic Science
Public Health Services Research
• CPH-01 Health Care Delivery/Access/Quality
• CPH-02 Health Economics and Cost-Effectiveness and Economics of Care
• CPH-03 Other public health issues
Miscellaneous-Clinical
• CM-01 Miscellaneous issues-Clinical
Miscellaneous-Basic
• BM-01: Miscellaneous issues-Experimental
All Comments
Important Date
-
Conference Date
Mar 14
2018
toMar 18
2018
-
Nov 15 2017
Abstract Submission Deadline
-
Dec 20 2017
Draft paper submission deadline
-
Mar 18 2018
Registration deadline
Contact Information
- V Bhatia
- in******@apasl2018.in
- 91 *********
Submit Comment